Early Detection of Prostate Cancer in the European Union: Combining Forces with PRAISE-U - Beyond the Abstract

The PRAISE-U project, officially known as "Promoting Risk-Based Screening for Early Detection of Prostate Cancer in Europe," has kicked off in Brussels in April 2023. A recent editorial talks about the emerging approach in early detection of prostate cancer (PCa), highlighting how PRAISE-U can contribute to this crucial mission.

PRAISE-U distinguishes itself through its comprehensive approach. Collaborating with a consortium of multidisciplinary partners and drawing upon insights from previous research, the project seeks to develop risk-based PCa screening programs. By developing a flexible algorithm, PRAISE-U aims to improve the classic one-size-fits-all strategy of an elevated PSA and direct systematic prostate biopsies by applying an individualised multi-step risk stratification.

The first result of consortium efforts – a comprehensive living state-of-play document on outcomes, harm, benefit, and cost-effectiveness of PCa screening initiatives and practices in Europe – is expected by the end of 2023. As PRAISE-U continues to advance, it will continue to adapt to emerging best practices and the evolving landscape of PCa research and screening.

The project leading to this application has received funding from the EU4Health programme under Grant Agreement n° 101101217. Co-Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or HaDEA. Neither the European Union nor the granting authority can be held responsible for them.

Written by: Hendrik Van Poppel1 & Vera Vasilyeva2


  1. Department of Urology, KU Leuven, Leuven, Belgium; European Association of Urology Policy Office, Arnhem, The Netherlands
  2. European Association of Urology Policy Office, Arnhem, The Netherlands.

Read the Abstract